Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, has partnered with Invitae Corp., a leading medical genetics company, to expand education ...

Invitae, a medical genetic testing company, has filed for Chapter 11 bankruptcy and intends to continue the case without disrupting operations using cash on hand and while seeking to sell its business ...

– Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine – SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Invitae (NVTA ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

SAN FRANCISCO-- (BUSINESS WIRE)-- Invitae Corporation (NYSE:NVTA), a genetic information company, and TME Research, LLC today announced the initiation of a new clinical collaboration to evaluate the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min More than 4 million people have ...

(RTTNews) - Invitae (NVTA) said clinical results from its PROCLAIM trial, published in European Urology Oncology, showed that almost half of prostate cancer patients with clinically actionable ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. San Francisco genetic testing firm Invitae succeeded this ...

Friday, the FDA granted de novo approval for Invitae Corporation's NVTA Common Hereditary Cancers Panel, an in vitro diagnostic test that can help detect hundreds of genetic variants associated with ...

Invitae's business has been growing rapidly and there's still more growth on the horizon. The beaten-up stock is a risky buy given its significant losses and persistent cash burn. There's significant ...